Clinical trial · Interventional
PET/MR Imaging in Lung Cancer
Advancing Diagnosis and Treatment for Lung Cancer Patients Using Hybrid PET/MR Imaging and Novel Visualization Tools
NCT03739281CI-TRIAL-00063232terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Internal resources ended
Summary
Brief summary (as posted)
The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Diagnostic Test | — | UNRESOLVED |
| PET/MR | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Nuclear medicine imaging
- description
- Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
- interventionNames
- Diagnostic Test: PET/MR
- Diagnostic Test: PET/CT
Primary outcomes (1)
- measure
- Sensitivity and specificity of PET/MR vs. clinical routine PET/CT
- timeFrame
- 1-2 weeks after the initial inclusion.
- description
- Sensitivity and specificity of PET/MR scans will be compared with in clinical routine PET/CT examinations for lung cancer disease feature prediction.
Secondary outcomes (3)
- measure
- Prediction of treatment response and progression-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Referred to clinical PET/CT examination for investigation of lung disease. Exclusion Criteria: * Blood glucose level \>8.3 mmol/l * MR incompatible objects, e.g. metal implants, inside the body * Intolerance to gadolinium-based contrast agents, e.g. severe renal disease (GFR\<30). * Unable to give written consent.
References
Publications (0)
Data not yet available
No reference posted for this study.